Protective Effector Memory CD4 T Cells Depend on ICOS for Survival by Moore, Tamson V. et al.
Protective Effector Memory CD4 T Cells Depend on ICOS
for Survival
Tamson V. Moore
1, Bryan S. Clay
1, Caroline M. Ferreira
1, Jesse W. Williams
1, Magdalena Rogozinska
2,
Judy L. Cannon
1, Rebecca A. Shilling
1, Amanda L. Marzo
2, Anne I. Sperling
1*
1Committee on Immunology & Section of Pulmonary and Critical Care Medicine, Department of Medicine, The University of Chicago, Chicago, Illinois, United States of
America, 2Department of Immunology and Microbiology, Rush University Medical Center, Chicago, Illinois, United States of America
Abstract
Memory CD4 T cells play a vital role in protection against re-infection by pathogens as diverse as helminthes or influenza
viruses. Inducible costimulator (ICOS) is highly expressed on memory CD4 T cells and has been shown to augment
proliferation and survival of activated CD4 T cells. However, the role of ICOS costimulation on the development and
maintenance of memory CD4 T cells remains controversial. Herein, we describe a significant defect in the number of effector
memory (EM) phenotype cells in ICOS
2/2 and ICOSL
2/2 mice that becomes progressively more dramatic as the mice age.
This decrease was not due to a defect in the homeostatic proliferation of EM phenotype CD4 T cells in ICOS
2/2 or ICOSL
2/2
mice. To determine whether ICOS regulated the development or survival of EM CD4 T cells, we utilized an adoptive transfer
model. We found no defect in development of EM CD4 T cells, but long-term survival of ICOS
2/2 EM CD4 T cells was
significantly compromised compared to wild-type cells. The defect in survival was specific to EM cells as the central memory
(CM) ICOS
2/2 CD4 T cells persisted as well as wild type cells. To determine the physiological consequences of a specific
defect in EM CD4 T cells, wild-type and ICOS
2/2 mice were infected with influenza virus. ICOS
2/2 mice developed
significantly fewer influenza-specific EM CD4 T cells and were more susceptible to re-infection than wild-type mice.
Collectively, our findings demonstrate a role for ICOS costimulation in the maintenance of EM but not CM CD4 T cells.
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Introduction
Memory CD4 T cells are a critical component of protective
immunity to disease [1,2,3,4,5,6,7] as well as many pathological
immune responses [8,9,10,11,12]. Two classes of memory CD4 T
cells with unique biological roles have been distinguished by
differential expression of lymphoid tissue-homing molecules:
lymphoid-homing central memory cells (CD44
hiCD62L
+CCR7
+)
and circulating and tissue-homing effector memory cells
(CD44
hiCD62L
2CCR7
2) [13]. Effector memory (EM) CD4 T
cells have been shown to be highly differentiated and produce
effector cytokines (such as IL-4 or IFN-c) more rapidly than
central memory (CM) CD4 cells [13,14,15]. Conversely, CM CD4
cells have greater proliferative capacity and may be able to
differentiate to multiple lineages after re-activation [16,17]. The
survival and homeostatic proliferation of CM and EM CD4 T cells
are regulated differently: CM CD4 T cells express higher levels of
anti-apoptotic signaling molecules whereas EM CD4 T cells
undergo greater levels of homeostatic proliferation [18,19].
Collectively, these findings suggest that central and effector
memory CD4 T cells occupy distinct niches.
Costimulatory molecules that enhance proliferation and survival
(CD28 and OX40) have been found to enhance the development
of memory CD4 T cells [20,21,22]. As EM CD4 T cells are
thought to derive from highly proliferated CD4 T cells and ICOS
costimulation has been found to enhance proliferation of CD4 T
cells [23], we hypothesized that ICOS costimulation might play a
role in the development or homeostatic proliferation of EM CD4
T cells.
In this study, we find that in the absence of ICOS costimulation,
there is reduced survival of EM but not CM CD4 T cells. The
reduced population of EM CD4 T cells is associated with a
reduced population of cytokine-producing cells and reduced
protection against re-infection in ICOS
2/2 mice. Collectively,
our results demonstrate that ICOS costimulation regulates the
survival of protective effector memory CD4 T cells.
Results
ICOS-deficient mice have fewer effector memory
phenotype CD4 T cells
To determine whether ICOS might regulate the development
or survival of memory CD4 T cells, we investigated the pre-
existing population of memory phenotype CD4 T cells in
untreated ICOS
2/2 and ICOSL
2/2 mice compared to wild-type
mice. Central memory phenotype CD4 T cells were identified as
CD44
highCD62L
high CD4 T cells and EM phenotype CD4 T cells
were gated on CD44
highCD62L
low CD4 T cells (Figure 1A), as
previously described [13,24]. ICOS
2/2 mice had similar numbers
of naı ¨ve and central memory phenotype CD4 T cells compared to
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2/2 and ICOSL
2/2 mice have fewer effector memory phenotype CD4 T cells. Age-matched wild-type and ICOS
2/2 (B) or
ICOSL
2/2 (C & D) mice were sacrificed. Splenocytes (A–C) or cells from the lungs, lymph nodes, and blood (D) were harvested and stained for CD3,
CD4, CD44 and CD62L. Cells were gated on CD3
+CD4
+ cells then on CD44 and CD62L. Naı ¨ve cells are identified as CD44
2CD62L
+, effector memory
cells as CD44
+CD62L
2, and central memory cells as CD44
+CD62L
+. Representative plots with gating on naı ¨ve, central memory and effector memory
populations in wild-type, ICOS
2/2, and ICOSL
2/2 mice are shown (A). The total numbers of naı ¨ve, effector memory phenotype and central memory
phenotype cells in the organs of wild-type and ICOS
2/2 or ICOSL
2/2 mice were calculated from the percent of each population and total numbers of
cells in the organ. N$4 for each group.
doi:10.1371/journal.pone.0016529.g001
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phenotype CD4 T cells (Figure 1B). Similar to ICOS
2/2 mice,
ICOSL
2/2 mice had no defect in naı ¨ve cell numbers and a
dramatic defect in EM phenotype CD4 T cell numbers
(Figure 1C). ICOSL
2/2 mice also had a significant defect in the
number of central memory phenotype CD4 T cells, but this was
neither as consistent nor as dramatic as the defect observed in the
EM phenotype CD4 T cell population.
As well as being found in the spleen, EM CD4 T cells are also
found in the tissues, and a small population of EM CD4 T cells
traffics through the lymph nodes. Moreover, the spleen includes
both circulating cells and lymphoid-homing cells, and therefore
does not completely represent circulating cells. We investigated the
number of EM phenotype CD4 T cells in the blood, the lymph
nodes, and the lungs, which we chose as a representative tissue that
is highly exposed to environmental antigens. We found that
ICOS
2/2 and ICOSL
2/2 mice had fewer EM phenotype CD4 T
cells in all tissues examined (Figure 1D). Conversely, there was no
difference in central memory CD4 T cells and while there
sometimes appeared to be a defect in the CM and EM CD8 T
cells in ICOS
2/2 and ICOSL
2/2 mice, it was neither as
consistent nor as dramatic as the defect in ICOS
2/2 EM CD4
T cells (data not shown). Collectively, these results indicate that
ICOS costimulation regulates either the development or mainte-
nance of EM phenotype CD4 T cells that are present in the
lymphoid and non-lymphoid tissues.
EM phenotype CD4 T cells have been shown to accumulate
with age in untreated mice and humans [25,26,27]. We
investigated whether there was a difference in this accumulation
of memory cells with age in untreated wild-type (B6) and ICOS-
deficient (B6 ICOS
2/2 and ICOSL
2/2) mice. Strikingly, the rate
of accumulation of EM phenotype CD4 cells was approximately
five-fold less in the absence of ICOS costimulation (Figure 2A). In
contrast, there was no defect in the populations of naı ¨ve or central
memory phenotype cells in ICOS-deficient mice (Figure 2B). Nor
did ICOS-deficient mice have a reduced population of naı ¨ve CD4
T cells at any age (Figure 2C). These results suggest that ICOS
costimulation enhances either the development or maintenance of
effector memory phenotype cells.
ICOS-deficient effector memory phenotype CD4 T cells
have no defect in homeostatic proliferation
The defect in EM phenotype cells in ICOS
2/2 mice was
dramatic and suggested that there might either be a defect in
development or reduced homeostatic proliferation of these cells.
As EM phenotype cells develop in response to unknown antigens,
there was no straightforward way to test the development of the
cells. However, the homeostatic proliferation of these cells could
be tracked by treating mice with the thymidine analogue BrdU,
which is incorporated into the DNA of proliferating cells and
detectable by intracellular staining and flow cytometry. In two
experiments, wild-type and ICOS
2/2 or wild-type and ICOSL
2/2
mice were treated with BrdU, and BrdU incorporation during
treatment (due to proliferation) and BrdU loss after treatment (due
to proliferation and to death) were assessed. EM CD4 T cells in
ICOS
2/2 (Figure 3A) and ICOSL
2/2 mice (Figure 3B) incorpo-
rated BrdU at similar rates during treatment as EM CD4 T cells in
wild-type mice. Similarly, after stopping treatment, EM CD4 T
cells lost BrdU at similarrates inICOS
2/2and ICOSL
2/2 mice as
in wild-type mice. These findings indicate that the dramatic
reduction in EM phenotype CD4 T cells in ICOS
2/2 and
ICOSL
2/2 mice is not attributable to differences in homeostatic
proliferation.
ICOS deficiency reduces antigen-specific effector
memory CD4 T cell survival
As the reduced number of EM CD4 T cells in ICOS
2/2 mice
could not be attributed to proliferation, we hypothesized that this
deficiencycould be either dueto a defectingenerationor insurvival
of EM CD4 T cells. To follow the generation and survival of wild-
type and ICOS
2/2 EM CD4 T cells, we utilized an adoptive
transfer model. Naı ¨ve (CD62L
high) wild-type or ICOS
2/2
DO11.10 cells were transferred into hosts and the hosts were
subsequently immunized. Memory cell populations were followed
for over four months after the contraction of the primary response.
We found that the ICOS
2/2 memory CD4 T cell population
declined at a greater rate than the wild-type population (Figure 4A),
which was attributable to decreases in the EM CD4 T cell
population (Figure 4B) while there was little or no difference in the
CM CD4 T cell population (Figure 4C). Interestingly, at early time
points (days 21 & 54), there was not a significant difference in the
number of ICOS
2/2 and wild-type EM CD4 T cells (Figure 4B),
suggesting that the development EM CD4 T cells was not
significantly impaired by the absence of ICOS costimulation.
However, by day 141, the ICOS
2/2 CD4 memory cells were
largelyCD62L
high centralmemorycellswhiletherewasa significant
population of wild-type CD62L
low EM cells (Cell counts in
Figures 4A–C, representative graphs shown in Figure 4E). From
these data, we concluded that ICOS costimulation enhanced
antigen-specific effector memory cell persistence.
ICOS costimulation enhances the long-term persistence
of IL-4-producing effector memory CD4 T cells
To determine whether the reduced numbers of ICOS
2/2
memory CD4 T cells was associated with a reduction in cytokine-
producing memory CD4 T cells, memory CD4 T cells (enriched
for TCR-transgenic cells) were restimulated in an ELISPOT assay.
We quantified the numbers of IL-4-producing ICOS
2/2 and wild-
type TCR-transgenic cells at the early (day 21) and late (day 140)
memory time points. There were similar numbers of ICOS
2/2
and wild-type total memory cells (Figure 4A) and IL-4-producing
memory cells (Figure 4D) early after the contraction of the
immune response. After the cells had rested an additional four
months, there were severe defects in both the number of ICOS
2/2
effector memory cells (Figure 4B) and the number of IL-4-
producing memory cells (Figure 4D, right). Collectively, these data
suggest that ICOS costimulation enhances the long-term persis-
tence of IL-4-producing EM CD4 T cells.
ICOS-deficient mice are more susceptible to influenza,
and develop fewer effector memory CD4 T cells in
response to influenza infection
To determine the role of ICOS costimulation on the
development of memory in a physiological response, wild-type
and ICOS
2/2 or ICOSL
2/2 mice were infected with the PR8
strain of influenza A, and antigen-specific CD4 T cells were
identified by staining and enriching memory cells with a
hemagglutinin (HA, epitope 143–155)-specific I-A
d tetramer
(HA-tetramer), as previously described by Moon et al. [28,29].
To determine the number of memory cells that developed in the
presence or absence of ICOS costimulation, wild-type and ICOS
2/2
mice were infected then rested (Figure 5A). As previously seen by
Humphreys et al. [30], there was no difference in the weight loss after
primary influenza infection (Figure 5B) nor was there any defect in
the number of HA-tetramer
+ CD4 T cells at day 10 post-infection
(data not shown) in ICOS
2/2 as compared to wild-type mice.
However, by 39 days post-infection, ICOS
2/2 mice had significantly
Effector Memory CD4 T Cells Depend on ICOS
PLoS ONE | www.plosone.org 3 February 2011 | Volume 6 | Issue 2 | e16529fewer EM CD4
+HA-tetramer
+ cells than wild-type mice (Figure 5D,
representative plots in Figure 5C). Interestingly, the total number of
memory cells was not different, because ICOS
2/2 mice also had
significantly more CM CD4
+HA-tetramer
+ cells than wild-type mice
(Figure 5D). These results demonstrate that ICOS costimulation
enhances the development of antigen-specific EM CD4 T cells and
potentially reduces the development of central memory cells after
infection with influenza.
To determine the responsiveness of the wild-type and ICOS
2/2
memory CD4 T cells, we re-challenged PR8-infected wild-type
and ICOSL
2/2 mice with a strain of VSV expressing the
influenza hemagglutinin molecule, VSV-HA. We found signifi-
cantly fewer responding HA
+CD4
+ cells in ICOSL
2/2 mice than
wild-type mice (Figure 5E). After challenge with VSV-HA,
Figure 3. ICOS-deficient and wild-type effector memory
phenotype CD4 T cells undergo similar homeostatic prolifer-
ation. A. Wild-type and ICOS
2/2 mice were treated with BrdU for 21
days, then followed for a further 49 days without BrdU. Blood was
drawn periodically and red blood cell-depleted. The lymphocytes were
then stained for CD4, CD44, CD62L, and BrdU and analyzed by flow
cytometry. The percent BrdU
+ of CD44
+CD62L
2 CD4
+ cells was assessed
at each time point. B. Wild-type and ICOSL
2/2 mice were treated with
BrdU for 24 days, followed for 49 days, and analyzed similarly to A. N$4
for all groups.
doi:10.1371/journal.pone.0016529.g003
Figure 2. Effector memory CD4 T cells accumulate at a
significantly reduced rate in ICOS-deficient mice. Wild-type and
ICOS
2/2 or ICOSL
2/2 (ICOS-deficient) mice of various ages were
sacrificed. Splenocytes were harvested and stained for flow cytometry
as described in Figure 1. The total number of naı ¨ve, effector memory
phenotype and central memory phenotype cells in the spleens of wild-
type and ICOS-deficient mice of each age were calculated. For the
effector memory phenotype cells, linear regression was performed and
the p-value for effector memory phenotype cells (A) represents the
likelihood of the slopes of the linear regressions being identical. 2-way
ANOVA analysis of the data where there were precisely age-matched
mice revealed similar significance.
doi:10.1371/journal.pone.0016529.g002
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+ cells were CD62L
low, suggesting that this
population was highly activated by viral infection (data not
shown). Interestingly, this was true in the ICOSL
2/2 mice as well
as wild-type mice, suggesting that although ICOS-deficient
memory cells are largely CD62L
high, these cells are capable of
down-regulating CD62L when repeatedly stimulated.
To determine whether the reduced population of EM CD4 T
cells in ICOS
2/2 mice was associated with reduced protection to
re-infection, we infected Balb/c and ICOS
2/2 mice with the
influenza virus Hkx31, rested the mice for over 30 days, then
challenged with the more lethal strain of influenza, PR8 (Figure 5F).
PR8 and HKx31 have previously been found to share eight internal
Figure 4. ICOS
2/2 effector memory but not central memory CD4 T cells have a defect in survival. Wild-type (filled squares, solid black
line) and ICOS
2/2 (open triangles, dotted lines) DO11.10 cells were adoptively transferred into separate hosts that were immunized the next day with
OVAp and inactivated S. mansonii eggs, as previously described. On various days after immunization, hosts were sacrificed and the spleen and lymph
nodes were harvested. Spleen and lymph node cells were stained with biotin-labeled KJ1-26 antibody, enriched with anti-biotin MACS beads, and
then stained further for CD4, CD44, and CD62L and with a streptavidin-fluorochrome reagent to bind biotinylated KJ1-26 antibody. At some time-
points, a fraction of the isolated cells were restimulated for 48 hours with OVAp to identify cytokine-producing cells (D). A. Total numbers of CD4
+KJ1-
26
+ cells. B. Number of effector memory (CD44
+CD62L
low) CD4
+KJ1-26
+ cells. C. Number of central memory (CD44
+CD62L
high) CD4
+KJ1-26
+ cells.
Significance (p-value) in part B. reflects the likelihood that the curves are the same (i.e. that one curve would represent all of the data as well as two
separate curves for wild-type and ICOS
2/2 cells). D. Total numbers of IL-4-producing KJ1-26-enriched cells on day 140. E. Sample plots of DO11.10
and ICOS
2/2 DO11.0 memory populations at day 140. N$4 for every group at each time-point.
doi:10.1371/journal.pone.0016529.g004
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2/2 mice develop fewer effector memory cells in response to influenza infection and have reduced recall responses
and protection against re-infection. ICOSL
2/2 or ICOS
2/2 and wild-type Balb/c mice were infected i.n. with either the PR8 of influenza then
rested (Timeline shown in A). Lung, draining lymph node, and spleen cells were enriched for HA-specific cells and stained for CD4, HA-tetramer, and
negatively stained for CD8, CD11c, and CD19 (in one fluorochrome). Data represents the total number of HA-specific CD4 T cells in all organs. A.
Diagram of infection, resting time, and rechallenge time. B. Weight loss after primary infection. C. Sample plots of HA-tetramer staining on tetramer-
enriched cells and CD44/CD62L staining on HA-tetramer
+ CD4 T cells from day 39 post-infection (quantified in D). D. (left) Total HA-tetramer-specific
Effector Memory CD4 T Cells Depend on ICOS
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infection but to have different coat proteins (hemagglutinin &
neuraminidase), preventing humoral protection [31,32]. After
challenge with PR8 virus, wild-type mice lost little weight, but
ICOS
2/2 mice lost nearly as much weight after secondary infection
as they had during primary infection with PR8 (Figure 5G and 5B).
These findings suggest that ICOS
2/2 mice had dramatically
reduced T-mediated protection to re-infection compared to wild-
type mice, associated with the reduced effector memory CD4 T cell
population in ICOS
2/2 mice.
Discussion
In this study we demonstrate that ICOS costimulation regulates
the survival of EM but not CM CD4 T cells. ICOS-deficient mice
had significantly fewer EM phenotype CD4 T cells, a defect that
became progressively greater with age. Interestingly, ICOS-
deficient EM CD4 T cells had no defect in homeostatic
proliferation, nor was there a defect in the early development of
EM CD4 T cells from activated cells. In contrast, there was
significantly reduced survival of ICOS-deficient EM CD4 T cells
compared to wild-type EM CD4 T cells. This defect was not
observed in ICOS-deficient central memory cells nor did we find
any defect in EM or CM CD8 T cells. Furthermore, the defect in
effector memory CD4 T cells after infection with influenza was
associated with significantly more weight-loss after challenge with
a heterosubtypic influenza strain. Collectively these results indicate
that ICOS costimulation regulates the long-term survival of EM
CD4 T cells that produce cytokines and mediate protection
against re-infection.
Our findings may resolve some of the controversy surrounding
the role of ICOS in the maintenance of memory CD4 T cells.
Although a study by Burmeister et al. found that ICOSL
2/2 mice
have fewer EM phenotype CD4 T cells [33], a second study by
Mahajan et al. found no defect in the polyclonal memory CD4 T
cell population in ICOS
2/2 mice [34]. Our findings now
demonstrate that ICOS costimulation enhances the survival of
EM phenotype CD4 T cells and antigen-specific EM CD4 T cells,
but the defect in EM CD4 T cells may be camouflaged by
compensatory increases or equivalent numbers of central memory
CD4 T cells. Specifically, we found that ICOS
2/2 and wild-type
mice had similar numbers of total CD4 memory cells, akin to the
study by Mahajan et al. [34], but closer investigation revealed that
ICOS
2/2 mice had more CM and fewer EM CD4 T cells
(Figure 5D). ICOS costimulation might regulate EM CD4 T cell
survival by either enhancing the development of EM CD4 T cells
that are capable of long-term survival or by enhancing the survival
directly, perhaps through continuous anti-apoptotic signaling. In
support of the latter possibility, previous studies have shown that
ICOS costimulation can enhance the expression of anti-apoptotic
molecules in CD4 T cells [35,36]. Our study therefore supports a
role for ICOS costimulation in the maintenance of the EM CD4 T
cell population, even when there is no effect of ICOS on the total
number of memory cells.
A cohort of individuals with chronic variable immunodeficiency
(CVID) have been found to have a genomic deletion resulting in
homozygous loss of ICOS [37]. CVID is characterized by reduced
antibody titers in the blood, especially class-switched antibodies
and increased susceptibility to infection. ICOS costimulation has
previously been shown to play an important role in T-dependent B
cell responses [38], but this may not be the only way in which
ICOS-deficiency impairs immune function in ICOS-deficient
CVID patients. Takahashi et al. have previously demonstrated
that ICOS-deficient CVID patients did have fewer memory T
cells, and the defect was most profound in CD62L
low memory
CD4 T cells [39]. In this study, we demonstrate that ICOS-
deficient EM CD4 T cells have defective survival, and in ICOS-
deficient patients, CVID is not usually diagnosed until adulthood
[37], a point at which the population of naı ¨ve CD4 cells is
declining and the body begins to depend more on memory cells
[40]. Specifically, effector memory CD4 T cells may play
important roles in protection against infection [41,42,43,44].
Our data suggest that individuals with ICOS deficiency may have
progressively worsening defects in their EM CD4 T cell mediated
protection, perhaps leading to progressively worse immunodefi-
ciency and recurring infections.
Due to its effects in reducing T-dependent B cell responses and
Th2 responses, ICOS costimulation is under consideration as a
potential target for clinical applications such as treatment of
asthma and cancer [45,46]. Our study demonstrates that EM CD4
T cells depend on ICOS costimulation for long-term survival,
suggesting that ICOS-blockade might reduce the survival of EM
CD4 T cell populations and enhancing ICOS costimulation might
augment the survival of these populations. Understanding how
ICOS regulates the development and the survival of EM CD4 cells
may enhance novel vaccination strategies aimed at inducing
protective EM CD4 T cells [41,44] and regulatory strategies to
control CD4 responses in diseases such as atopic asthma that are
exacerbated by EM CD4 T cells [47,48,49,50,51,52].
Materials and Methods
Ethics Statement
All animal studies were done in concordance with principles set
forth by the Animal Welfare Act and the National Institutes of
Health guidelines for the care and use of animals in biomedical
research and were reviewed and approved by the University of
Chicago Institutional Animal Care and Use Committee.
Mice
B6 mice were purchased from Charles Rivers Laboratories
(Boston, MA). ICOS
2/2 (B6.ICOS
2/2) mice were a generous gift
of Dr. Flavell and have been previously described [53]. Balb/c
ICOS
2/2 and B6.ICOSL
2/2 mice were a gift from Dr. Andrew
Welcher (Amgen, Thousand Oaks, CA). DO11.10 and
CBy.PL(B6)-Thy1a/ScrJ (Balb/c Thy1.1) mice were purchased
from the Jackson Laboratory (Bar Harbor, ME). Balb/c ICOS
2/2
mice were crossed to DO11.10 mice to generate DO11.10
+
ICOS
2/2 mice. Animals were housed in a specific pathogen-free
facility maintained by the University of Chicago Animal Resources
Center (Chicago, IL).
DO11.10 adoptive transfer model
DO11.10 and ICOS
2/2 DO11.10 mice were sacrificed, and
spleen and lymph node cells were enriched for T cells by passage
over a nylon wool column [54]. T-enriched cells were further
CD4+ T cells at 39 days after PR8 infection, (middle) CD44
+CD62L
+ HA-tetramer
+ CD4
+ central memory cells, and (right) CD44+CD62L- HA-tetramer+
CD4+ effector memory cells. E. Total HA-tetramer-specific CD4 T cells in wild-type and ICOSL
2/2 mice infected with PR8 then challenged 85 days later
with re-infection with VSV-HA. F. Timeline for Hkx31 infection and PR8 challenge. G. Weight loss in ICOS
2/2 and wild-type mice after infection with
Hkx31 followed 60 days later by challenge with PR8 virus.
doi:10.1371/journal.pone.0016529.g005
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+ naı ¨ve cells by MACS separation with anti-
CD62L beads (Miltenyi Biotec, Auburn, CA). The CD62L
+
enriched T cells were then stained with CFSE to track cell division
[55]. A sample of enriched cells was stained for CD4, KJ1-26, and
CD62L and run on the LSR II flow cytometer to identify the
percentage of transgenic cells.
One million CD4
+KJ1-26
+ cells were transferred to naı ¨ve hosts
by i.v. injection in 100 microliters of DMEM media. One day
later, the hosts were then immunized intraperitoneally with 200
micrograms of ovalbumin peptide (ovalbumin 323–339, Protein-
Peptide Core Facility, University of Chicago, Chicago, IL) and
2500 inactivated Schistosoma mansonii eggs (Joel Weinstock, Tufts
University–New England Medical Center, Boston, MA), which
were inactivated as previously described [56,57], and serve as a
Th2 adjuvant [58,59,60,61,62].
At various time-points after immunization, the hosts were
sacrificed, and splenocytes and lymph node cells were collected.
Adoptively transferred cells were enriched by MACS sorting of
splenocytes and lymph node cells stained with biotinylated KJ1-26
antibody and anti-biotin beads as described by Hataye et al. [63].
KJ1-26-enriched and KJ1-26-depleted cells were counted, stained
and analyzed by flow cytometry.
Influenza Infection
A/PR8/34 (PR8, H1N1) and A/Hkx31 (HKx31, H3N2) were
gifts from Dr. Stephen M. Tompkins (University of Georgia,
Athens, GA). VSV-HA, expressing the PR8 hemagglutinin protein
[64] was a gift from Dr. Elizabeth A. Ramsburg (Duke Univesity
Human Vaccine Institute, Durham, NC). Wild-type and ICOS
2/2
Balb/c mice were infected intranasally with 500 plaque forming
units (PFU) of the PR8 strain of influenza. On the specified days
afterinfection,themicewereeithersacrificedinordertoidentifythe
number of antigen-specific cells or re-infected intranasally with
10,000 PFU of VSV-HA. When mice were sacrificed, broncheoal-
veolar lavage (BAL) was performed and the spleens, lung-draining
mediastinal lymph nodes, and lungs were taken and processed.
To infect and challenge with strains of influenza, wild-type and
Balb/c ICOS
2/2 mice were first infected with 5000 PFU of the
Hkx31 strain of influenza. On the specified day after infection,
mice were challenged with 5000 PFU of the PR8 strain of
influenza. Weight loss was monitored daily after challenge and a
cohort of mice were sacrificed five days after challenge to take viral
titers.
Lung Processing
Lungs were perfused with 10 mL PBS with 50 units/mL
heparin, injected through the right ventricle of the heart. Then the
lung was surgically excised and cut into small pieces. The pieces
were incubated in a shaker at 37uC for one hour in DMEM media
with 30 U/mL Collagenase IV. Any remaining pieces of tissue
were removed by straining the solution through a nytex filter, and
the cells in suspension were centrifuged and resuspended in
DMEM + 5% FCS.
Hemagglutinin Tetramer Staining and Enrichment
The hemagglutinin tetramer consists of a PE-labeled streptavi-
din core binding four biotinylated I-A
d-HA (143–155) monomer
subunits. Tetramers were kindly provided by the NIH Tetramer
Core Facility at Emory University (Atlanta, GA). Single cell
suspensions were stained with PE-labeled hemagglutinin tetramer
by incubating cells with 20 mg/mL of tetramer, diluted in 2.4G2
with 2% mouse and 2% rat serum, for 3 hours at 4uC. Spleens
were labeled in 100 microliters of tetramer solution; lymph nodes,
lungs, and BAL cells were each labeled in 50 microliters of
tetramer solution. After labeling, the cells were washed in MACS
buffer then incubated at 4uC for 20 minutes with anti-PE magnetic
beads. Finally, bead-labeled cells were washed in MACS buffer
then run over magnetic columns to enrich for tetramer-positive
cells. All of the tetramer-enriched cells and a sample portion of the
tetramer-depleted cells were stained with antibodies and run on a
flow cytometer.
5-bromo-2-deoxyuridine (BrdU) treatment and analysis
Mice were injected in their intraperitoneal cavity (IP) with 2 mg
of BrdU (Sigma-Aldrich, St. Louis, MO) in 200 mL of PBS on a
daily basis for 24 days. After 24 days, BrdU treatment was ceased.
BrdU uptake was analyzed during and after BrdU treatment on a
weekly basis by staining peripheral blood lymphocytes (PBL)
isolated from approximately 150 mL of mouse blood. The blood
was separated over a Histopaque 1083 (Sigma-Aldrich, St. Louis,
MO) gradient, saving the interface cells. The separated viable
mononuclear cells were stained for CD4 cell markers first (as
described in Flow Cytometry) then for BrdU, using the protocol
and reagents from the FITC BrdU Flow Cytometry Kit (BD
Biosciences, San Jose, CA). Identification of BrdU positive cells is
based on BrdU staining of treated mice versus an untreated
control mouse (to identify background staining).
ELISPOT analysis
Plates were pre-incubated with unlabeled coating antibody for
IL-4 (BD Bioscences, San Jose, CA) according to the manufac-
turer’s protocol. For the cell stimulation, KJ-126-enriched cells
were incubated on the coated plates for 48 hours with OVA
peptide (1 mg/mL) or no antigen and 1.0610
6 splenocytes were
added as antigen-presenting cells. After cell stimulation, the plates
were then sequentially treated with the biotinylated secondary
antibody, streptavidin-HRP and AEC (3-Amino-9-ethyl-carba-
zole) solution according to the manufacturer’s protocol. The
number of spots was calculated by the ImmunoSpot plate reader
(Cellular Technology LTD., Shaker Heights, OH). The number of
spots per million cells was calculated based on cellular input and
was then multiplied by the total number of cells to find the total
number of IL-4 producing cells.
Flow cytometry
Prior to staining with antibodies, cells were washed once and
blocked and nonspecific antibody binding was blocked with anti-
FccR (2.4G2) antibodies. Antibodies were purchased from BD
Biosciences (San Jose, CA), eBioscience (San Diego, CA), and
Biolegend (San Diego, CA), and included: KJ1-26 (for DO11.10
TCR idiotype), anti-Va2 (clone B20.1), anti-Vb5 (MR9-4), anti-
CD44 (PGP-1), anti-CD62L (MEL-14), anti-CD4 (RM4-5), anti-
CD3 (2C11), anti-ICOS (C398.4A & 7E.17G9), anti-CD69
(H1.2F3), anti-CCR7 (4B12) [Note: CCR7 required staining at
37uC], anti-CD45.1 (Ly5.1, clone A20), and anti-CD45.2 (Ly5.2,
clone 104). After primary staining, the cells were washed three
times then secondary antibodies (streptavidin-PE, streptavidin-
APC, or streptavidin-APC-Cy7) were added and cells were
incubated for 30 minutes at 4uC. Then cells were washed three
more times and then run on a LSR II flow cytometer (BD
Biosciences San Jose, CA) and analyzed using FlowJo software
(TreeStar, Ashland OR).
Data analysis and statistics
Microsoft Excel was utilized to calculate fractions and numbers.
Data was then further analyzed and presented using Prizm 5.0
software (GraphPad Software, San Diego, CA). A student’s t-test
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significantly different. Two-way ANOVA was utilized to deter-
mine if one population changed over time differently than another
population. If p#0.05, results were considered significant.
*p#0.05; ** p#0.01; ***p#0.001.
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